Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003655509 | SCV004382658 | uncertain significance | RASopathy | 2023-06-24 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with SOS1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1171 of the SOS1 protein (p.Ile1171Val). |
Ambry Genetics | RCV004371535 | SCV005023615 | uncertain significance | Cardiovascular phenotype | 2024-01-17 | criteria provided, single submitter | clinical testing | The p.I1171V variant (also known as c.3511A>G) is located in coding exon 23 of the SOS1 gene. The isoleucine at codon 1171 is replaced by valine, an amino acid with highly similar properties. This change occurs in the first base pair of coding exon 23. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |